Turn Biotechnologies

12:15 PM - 12:30 PM (PDT), Tuesday, June 14, 2022
Turn is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company’s proprietary mRNA platform technology, ERA™, combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. This restores the cells’ ability to prevent or treat disease and heal or regenerate tissue and will help to fight incurable chronic diseases.

Turn’s technology provides a platform from which to attack a variety of now incurable chronic diseases. The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Cell rejuvenation (Dermatology and Immunulogy)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Executive Officer
Turn Biotechnologies